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ABSTRACT
Animal model studies and clinical trials have looked at the potential benefits of the antiinflammatory properties of statins in asthma management with contradictory results. Therefore,
the objective of this study is to determine if asthma patients on concurrent statin therapy are less
likely to have asthma-related hospitalizations and emergency room (ER) visits.
We conducted a retrospective cohort study using Medicaid data for 2002-2004. Asthma
patients 18 years old were identified using the ICD9 code 493.xx, from Jul 1, 2002 through Dec
31, 2003. The index date for an exposed subject was any date within the identification period,
180 days prior to which the subject had at least 1 inhaled corticosteroid (ICS) prescription and at
least an 80% adherence rate to statins. Medicaid beneficiaries identified as asthmatics and on
ICS therapy, but not on statins were selected as the unexposed population. Each subject in the
exposed group was matched to 2 subjects from the unexposed population using propensity scores
computed using age, gender, race, urban/rural region and Charlson Comorbidity Index. The two
groups were followed for 1 year beginning on the index date, and their outcomes in terms of
hospitalizations and ER visits were compared using conditional logistic regression, further
adjusted for adherence to ICS therapy, average number of short-acting β agonists per subject,
prior hospitalizations, ER, lab and office visits due to asthma.
After matching, there were 479 exposed subjects with 958 corresponding controls. After
adjusting for the above mentioned covariates, asthma patients not on concurrent statin therapy
are almost two times as likely to have hospitalization and/or ER visits or both due to asthma
(adjusted OR = 0.55; 95% CI [0.37, 0.84]; p = 0.0059), in comparison to patients on statin
ii

therapy. Similarly, they are also twice as likely to visit the ER due to asthma exacerbations as
patients on statins (adjusted OR = 0.48; 95% CI [0.28, 0.82]; p = 0.0069).
The findings of this study suggest that there may be beneficial effects of statins in
preventing asthma exacerbations. Further prospective investigations are required to provide
conclusive evidence.
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I. INTRODUCTION
Asthma is a chronic inflammation of the airways, leading to poor air exchange that
causes shortness of breath and wheezing. Around 300 million across the globe1 and 22 million
in the United States2 are afflicted with the disease leading to an annual burden of approximately
$20.7 billion dollars (2010)3 to the U.S. health care system. Medications used in the
management of the disease are categorized into acute relief and long-term maintenance, with
Inhaled Corticosteroids (ICSs) being the most widely prescribed for long-term control of the
condition. Recently, there has been considerable discussion about the anti-inflammatory
properties of statins and hence their potential therapeutic benefit in the treatment of asthma.
Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzymes A (HMG CoA)
reductase, conventionally prescribed as anti-hyperlipidemics. However, their beneficial antiinflammatory properties have led to several studies evaluating their role in the management of
asthma. Animal model studies4-10 suggest various mechanisms of action by which statins may
have potential benefits in the treatment of asthma with promising results. There have been two
published clinical trials11,12 that have reached conclusions that conflict the findings of the animal
model studies. Here, the authors failed to find statins effective for the short-term therapy of
asthmatic inflammation, but one of them documented a reduction in the sputum macrophage
counts in mild to moderate atopic asthma. It should be noted that the clinical trials have sample
size limitations.
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There has been one retrospective analysis13 so far that investigates the relationship
between statins and asthma outcomes using the Medco National Integrated Database. This study
concludes that statin exposure is independently associated with a significant 33% relative risk
reduction for recurrent asthma- related hospitalizations and emergency room (ER) visits.
Some researchers are of the opinion that we already have effective medications for the
treatment of allergic asthma in the form of ICS and that adding a statin to an appropriate dose of
ICS would not provide any additional benefit for patients with asthma.14 But, in spite of ICS
being an effective therapy, the burden of asthma, in terms of healthcare dollars and loss of
productivity, continues to increase.3,15
Thus, we are left with exciting data but a nagging dilemma and results so far clearly
suggest that more studies investigating the potential role of statins in the management of asthma
are required to make any clinical or policy-guiding decisions. In light of the evidence so far, the
purpose of this study is to investigate the potential role of statins on asthma outcomes in
particular, using a retrospective cohort study design, with the specific objectives being:
1. To describe the baseline characteristics such as age, gender, race of Medicaid
beneficiaries with asthma who are on statin therapy and those not on statin therapy.
2. To compare the outcomes, using ER visits and hospitalizations as a measure, amongst
asthmatic Medicaid beneficiaries on statin therapy to those not on statin therapy.
3. To compare the costs incurred by asthmatic Medicaid beneficiaries on statin therapy to
those not on statin therapy including the prescription costs, ER visits and hospitalization
costs.
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II. LITERATURE REVIEW
Asthma Prevalence and Costs
Approximately 300 million people across the globe suffer from asthma according to the
executive summary of the Global Initiative for Asthma (GINA) Dissemination Committee
Report. 1 The GINA program was initiated in 1989 in an effort to raise awareness about the
increasing prevalence of asthma worldwide, with the Dissemination Committee being
responsible for providing data on the burden of asthma. Estimates from the report also suggest
that asthma prevalence increases globally by 50% every decade with some of the highest
numbers seen amongst data from developed countries such as United Kingdom (>15%), New
Zealand (15.1%), Australia (14.7%), the Republic of Ireland (14.6%), and the United States
(10.9%). Numbers from the World Health Organization (WHO) fact sheet on bronchial asthma
attribute 180,000 deaths globally to asthma each year and estimate that the economic costs
associated with asthma exceed those of tuberculosis and HIV/AIDS combined.16 The financial
burden on patients with asthma in different western countries ranges from $300 to $1,300 per
patient per year17 with those suffering from severe asthma being responsible for 50% of all direct
and indirect costs even though this patient population represents just 10-20% of all those
suffering from the condition.15,18 Thus, the economic burden disproportionately affects those
with the most severe disease.
In accordance with the 2007 National Asthma Education and Prevention Program Expert
Panel Report 32 more than 22 million have asthma in the U.S. The burden of asthma affects
3

patients and their families in terms of lost work and school days, lessened quality of life, and
avoidable emergency department visits, hospitalizations and deaths. Estimates of the annual
costs of asthma in the U.S. range between $12.7 and $20.7 billion.3,19 Researchers at the
University of Georgia developed an estimate of the lifetime costs of asthma for children born in
the year 2000, documenting the total lifetime impact of asthma for this birth cohort to be $7.2
billion.20 They also concluded that losses in productivity are significant and thus interventions
that help better manage the disease, reduce the number of missed work days, and decrease the
number of asthma exacerbations could have significant indirect cost savings.
The National Surveillance for Asthma 2001- 2003 summary21 reported 55.6% of current
asthmatics as having one or more attacks during the preceding 12 months. Amongst other
statistics, the summary mentions an average annual 61.2 office visits, 6.7 hospital outpatient
visits and 8.8 emergency department visits for asthma per 100 persons with current asthma.
Analysis of cross-sectional survey data from an on-going community-based panel study of adults
with asthma based in northern California reported $4,912 as the total per person annual costs of
asthma with hospital admissions and indirect costs due to loss in productivity accounting for
9.75% and 35% of the total costs respectively.22 A review of various cost of illness studies
estimated the mean direct cost of asthma per year per patient to be $1,100 approximately, stating
it accounted for 50% of total costs.23 Thus, it is evident that significant healthcare savings can be
accrued if costs due to hospitalizations and loss of productivity are prevented via better
management of the condition, preventing asthma exacerbations.
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Asthma Treatment
Asthma has been defined as “a chronic inflammatory disorder of the airways in which
many cells and cellular elements play a role; in particular mast cells, eosinophils, neutrophils
(especially in sudden onset, fatal exacerbations, occupational asthma, and patients who smoke),
T lymphocytes, macrophages and epithelial cells. In susceptible individuals this inflammation
causes recurrent episodes of coughing (particularly at night or early in the morning), wheezing,
breathlessness, and chest tightness. These episodes are usually associated with widespread but
variable airflow obstruction that is often reversible either spontaneously or with treatment.”2
Airway inflammation is said to bring about a majority of the changes in the airway and thus
future studies are targeted at determining if different treatment approaches will benefit the
different patterns of inflammation. Definitive causes that bring about the inflammatory process
have not yet been established although genetics, environmental factors as well as the balance
between Th1- and Th2-type cytokine responses are amongst a few that have been suggested.24
Medications that attenuate the inflammation are the most effective in the management of
asthma symptoms and are currently classified as quick relief or long-term control medications.25
Controller medications are generally prescribed when quick-acting bronchodilators are needed to
relieve symptoms more than two days a week or more than twice a month for night time
awakenings caused by exacerbations.2,24 Figure I is a schematic diagram illustrating the stepwise
control of the disease.
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STEP 6

STEP 5
STEP 4

STEP 3
STEP 2
Preferred:
Low-dose
ICS

STEP 1
Preferred:
SABA

Alternative:
Cromolyn,
LTRA,
Nedocromil,
Theophylline

Preferred:
Medium dose
ICS + LABA

Preferred:
Low-dose
ICS + LABA
or medium
dose ICS

Alternative:
Medium dose
ICS + LTRA,
Zileuton,
Theophylline

Alternative:
Low dose
ICS + LTRA,
Zileuton,
Theophylline

Intermittent
Asthma

Preferred:
High dose
ICS + LABA
AND
Consider
Omalizumab
for patients
who have
allergies

Preferred:
High dose
ICS + LABA
+ oral
corticosteroid
AND
Consider
Omalizumab
for patients
who have
allergies

Persistent Asthma: Daily Medication

Figure I. Stepwise approach for Asthma Management in Adults (National Asthma Education and
Prevention Program Expert Panel Report 3)2
• SABA – Short Acting β Agonists
• LABA – Long Acting β Agonists
• LTRA – Leukotriene Receptor Antagonists

Inhaled Corticosteroids (ICSs) are the most consistently effective long-term control
medications at all steps of care for persistent asthma. They reduce airway hyper responsiveness,
inhibit inflammatory cell migration and activation and block late phase reaction to allergens.2
ICSs reduce impairment and risk of exacerbations but evidence to suggest they prevent the
progressive decline in lung function is lacking.26,27 Strategies that achieve asthma control
without using high doses of ICS are desirable as the dose therapeutic response curve for these
medications is relatively flat whereas the dose-systemic absorption curve appears to be linear.28
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This indicates an increasing availability of the drug in the systemic circulation with increasing
doses; however, the therapeutic benefits achieved do not necessarily differ with higher doses.
Cromolyn sodium and nedocromil, immunomodulators that prevent binding of IgE to the
receptors on basophils and mast cells, leukotriene modifiers, long-acting β agonists (LABAs) and
methylxanthines are some of the other long-term control medications. Leukotriene modifiers
and LABAs are generally used in combination with ICSs. Anticholinergics, short-acting β
agonists (SABAs) and systemic corticosteroids are the quick-relief medications used to treat
acute symptoms and exacerbations.2,24

Statins in the Treatment of Asthma
Recently statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzymes A (HMG-CoA),
have been shown to have promising therapeutic potential in mediating inflammatory processes.2932

They are amongst the most widely prescribed medicines and are primarily used to treat

hyperlipidemia and prevent cardiovascular diseases. However, in the past decade studies have
shown statins to be effective in animal model studies as well as clinical trials of rheumatoid
arthritis33-35, autoimmune encephalomyelitis36,37, inflammatory colitis38,39 and even psoriasis40
due to their anti-inflammatory properties. Given this, there has been some discussion pertaining
to the use of statins in the treatment of asthma and various studies have suggested asthma
management as an emerging indication for statins.41-45
Certain researchers believe that the addition of a statin to ICS therapy in clinical practice
will not prove beneficial in the management of asthma referring to this setting as a ‘snake oil
panacea’14, while others believe it might actually be harmful.46 These have just been voiced as
7

opinions in the literature and there is lack of evidence in support of these concerns.
Alternatively, the majority of the arguments are in favor of adding a statin to ICS therapy, and
not without evidence. A number of studies have shown the beneficial effects of statins in the
management of asthma and these will be discussed shortly. It has been suggested that statin
treatment could improve asthma control in smokers with asthma who are insensitive to treatment
with ICS.47,48 Additionally, some patients with severe asthma require additional oral
corticosteroids, a long-term treatment which is associated with such side effects as adrenal
suppression, growth suppression, and osteoporosis.42,49 Statins on the other hand are one of the
most widely prescribed medications and have a better safety profile. In certain cases severe
asthma is steroid-resistant, and hence alternative therapy is needed for such patients.49
It has been suggested that the pleiotropic effects of statins are independent of their lipidlowering abilities45, 50 and are in part related to their lipophilicity, and thus each compound in the
class exhibits different effects on the inflammatory cells. Simvastatin and atorvastatin are said to
have the greatest anti-inflammatory potential.51 The rationale behind this observation is the
preferential ability of lipophilic statins to enter a variety of somatic cells, in contrast with
hydrophilic compounds such as pravastatin that are reliant on active uptake by hepatocytes to
mediate their metabolic activity.52 Hence, important within class differences exist between the
drugs.
A few animal model studies suggest that statins might have potential as therapeutic
agents in the treatment of asthma.4-10 Y. Chiba et al. have carried out a number of such studies
with lovastatin. Their experiments with rats suggest that systemic lovastatin inhibits antigeninduced bronchial smooth muscle hyper-responsiveness in addition to reducing the increased cell
number in bronchoalveolar lavage (BAL) fluids and histological changes induced by antigen
8

exposure.4 They also demonstrated that levels of Immunoglobulin E in sera and interleukins -4, 6, and -13 in the bronchoalveolar lavage fluids were not significantly changed. The authors have
carried out similar experiments in mice, with findings that support the beneficial role of statins in
asthma management.5 The proposed mechanism of action for this observation is that statins
inhibit the geranylgeranylation of a monomeric GTP binding protein RhoA and its downstream
metabolites, which are involved in the agonist induced Ca2+ sensitization of airway smooth
muscle contraction. The RhoA/ RhoA kinase pathway is now being investigated as the new
target for the treatment of airway hyper responsiveness.
Another animal model study conducted by Y. Chiba et al. shows that lovastatin
ameliorates the antigen induced infiltration of inflammatory cells such as eosinophils into the
airways.6 Inhibition of the geranylgeranylation of Rho family GTPases in leukocytes has been
cited as the proposed mechanism again. Similarly, a study conducted by McKay and colleagues
showed the inhibitory effects of simvastatin on inflammatory cell infiltration in a murine model
of allergic asthma.7 They also showed a reduction in the BAL cytokine levels which is
contradictory to the results of the experiments conducted by Y. Chiba and colleagues.
Similarly, experiments have been conducted with pravastatin and simvastatin showing
beneficial effects whereby the former was shown to suppress systemic sensitization to allergen
due to inhibition of interleukin 178 and the latter prevents the infiltration of inflammatory cells in
the bronchoalveolar lavage fluids9 and has been shown to reduce the CD4 T cell numbers.10
Apart from the animal model studies described above, two clinical trials have been
conducted, whereby the relationship between statins and asthma has been further explored. A
randomized double-blind crossover placebo controlled trial was designed to investigate the effect
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of oral atorvastatin on measures of asthma control and airway inflammation in 54 adults with
allergic asthma receiving inhaled corticosteroids alone.11 The authors found no clinically
important improvements in a range of clinical indices of asthma control despite expected
changes in serum lipids and thus concluded that statins were ineffective for the short-term
therapy of asthmatic inflammation. However, a change in the airway inflammation, as well as a
reduction in the sputum macrophage count was observed indicating that statins could have
beneficial effects in other chronic lung diseases.
A similar clinical trial using oral simvastatin was conducted using 16 patients with
asthma whereby the authors found no improvement in asthma symptoms, pulmonary function or
measures of asthmatic inflammation.12 All anti-inflammatory asthma medications including
inhaled corticosteroids were tapered and stopped completely for the duration of this study, which
was the major difference in the protocols of the two clinical trials. However, a small sample size
is one of the major limitations of the above cited clinical trials and thus the results should be
interpreted cautiously.
In 2007, E. Stanek and colleagues conducted an observational study using the Medco
National Integrated Database to explore the relationship between statin treatment and asthma.
This is the first observational study to investigate the topic.13 A total of 6,574 inhaled
corticosteroid-treated adult asthmatics were studied and statin exposure was independently
associated with a significant 33% relative risk reduction for recurrent asthma-related
hospitalization/ER visits over 12 months. They included subjects who had received an ICS
prescription anytime from January 2006 to December 2006 and had recorded at least one asthma
specific hospitalization/emergency room visit in the 12 months prior to the index ICS
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prescription selected. These were then stratified by statin exposure following evidence of an
index ICS prescription.

Study Purpose
With the above study being the only retrospective database analysis conducted so far to
explore the role of statins in the management of asthma, further such studies are warranted.
Additionally, a definitive conclusion regarding the potential benefits of statins in the treatment of
asthma has not yet been reached as the various animal model studies and clinical trials described
above show varying results and have their own limitations. Thus, another secondary database
analysis, using a different dataset, will be economically more feasible and will provide us with
an overview of the situation in the real-world setting. This study uses a propensity score
matched cohort study design which in itself should take into account any confounding effects
due to the variables used to compute the propensity scores. Prior hospitalizations, ER and office
visits due to asthma, compliance to ICS medications and average number of short-acting β
agonists during the study period were used to compute the propensity scores. These had not
been taken into account in the study conducted by E. Stanek and colleagues. Prior
hospitalizations due to asthma and average number of short-acting β agonists can be an indicator
of the severity of the disease, whereas compliance to the medications is a potential confounder as
it could lead to hospitalization/ER visits. Thus, conducting a study on a different dataset with a
different study design will make a significant addition to the research done so far on this topic.
Moreover, the results of this study will aid in the decision as to whether to design further clinical
trials on larger scales.
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Bearing the significance in mind, the purpose of the study is to make explicit the role of
statins in the management of asthma in the real-world setting. There seems to be some
ambiguity concerning the potential anti-inflammatory benefits of the HMG-CoA reductase
inhibitors for asthmatic patients with the animal model studies and the observational study
showing positive results and the clinical trials suggesting otherwise. Thus, this study can provide
additional evidence to help make the picture clearer, as it will overcome some of the limitations
of the work done so far.
To achieve the above purpose, the main objectives of this study are
1. To describe the baseline characteristics such as age, gender, race of Medicaid
beneficiaries with asthma who are on statin therapy and those not on statin therapy.
2. To compare the outcomes, using ER visits and hospitalizations as a measure, amongst
asthmatic Medicaid beneficiaries on statin therapy to those not on statin therapy.
3. To compare the costs incurred by asthmatic Medicaid beneficiaries on statin therapy to
those not on statin therapy including the prescription costs, ER visits and hospitalization
costs.
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III. METHODS AND STUDY DESIGN
A retrospective cohort study of the Mississippi Medicaid claims database was conducted.
The study involved analysis of the Medicaid beneficiary claims from January 1st 2002 to
December 31st 2004. As mentioned earlier, the primary objective of this study was to compare
the asthma related outcomes- ER visits, hospitalizations- of Medicaid beneficiaries diagnosed
with asthma and on concurrent statin therapy versus those not on statin therapy. Apart from this,
the study also looked into the costs incurred by asthmatic Medicaid beneficiaries on statin
therapy versus those not on statin therapy in terms of prescription costs, hospitalization and ER
visits costs. The study was approved by the Institutional Review Board (IRB) of the University
of Mississippi.

Data Source
Medicaid is a federal health care program that provides health care coverage to many of the
most vulnerable populations in the United States, including low-income children and their
parents, low-income elderly, pregnant women with low family income and the disabled poor.
The program is jointly run by the federal and state governments whereby the former establishes
general guidelines for the program and the latter decides upon the eligibility criteria.
The Mississippi Medicaid claims database was used for this study. It is an administrative
claims database, comprising of one Person Summary File and four Claims Files - inpatient (IP),
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institutional long-term care (LT), prescription drug (RX) and other services (OT). The Person
Summary File is created to include person level data on eligibility, demographics, managed care
enrollment, a summary of utilization and Medicaid payment by type of service. Whereas, each
observation in the claims files represents a transaction or record of the payment made to the
health care provider for the services offered by him/her to the Medicaid enrollee, including
details like the date of service, expenditures for utilized services, associated diagnostic
information, and provider and procedure type. The person summary file has a record for every
individual enrolled in the program at anytime during the year; however, the claims files may
have more than one or no records for a Medicaid beneficiary depending on his/her utilization of
the services. The following variables from each dataset were used in the study:
1. Medicaid Analytic Extract Personal Summary Record: It contains a record for each unique
person, based on his/her MSIS Identification Number, which is a unique number used to
identify a Medicaid eligible in the Medicaid Statistical Information System (MSIS). The
unique encrypted patient identification number was used as the linking variable to club
records of a particular patient from all the other data files into one file. The other variables
that were required from the personal summary record are eligible birth date, eligible sex
code, eligible race/ethnicity code, eligible residency county and max uniform eligibility code.
2. Medicaid Analytic Extract Inpatient Record: The inpatient record provides information on
inpatient hospital stays for each patient. The MSIS type of service code, Medicaid payment
amount, the principal diagnosis code as well as all the other diagnoses codes were the fields
used from this file.
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3. Medicaid Analytic Extract Drug Record: The drug record provides information on drugs and
other services provided by a pharmacy for each recipient. The Medicaid payment amount,
prescription filled date, new or refill indicators, NDC, quantity of service and days’ supply
were the required fields.
4. Medicaid Analytic Extract Other Services Record: The other services record provides
information on services for each recipient, other than those provided by an inpatient hospital,
long term care facility or pharmacy. The diagnoses codes from this record were also used to
identify asthmatic patients. Additionally, the procedure codes and place of visit codes were
used to identify office and lab visits attributed to a primary diagnosis of asthma.

Study Period and Study Population
The Medicaid records from January 1st 2002 through December 31st 2004 were analyzed.
It is important to note here that, since the study period under consideration is prior to the
implementation of Medicare Part D, the database does include elderly patients. Asthmatic adults
above 18 years of age were identified using the ICD9 code 493.xx, within the 18 month
identification period starting July 1st 2002 and concluding December 31st 2003 as graphically
represented in Figure II. The index date for a particular subject in the exposed group was any
date within the identification period, six months prior to which the subject had at least one
prescription for an inhaled corticosteroid (ICS), at least an 80% adherence rate to statins (i.e. a
medication possession ratio (MPR) of 0.8), in addition to already having been diagnosed with
asthma. The subjects on statin and ICS therapy were identified using the National Drug Codes
(NDC) for these drugs respectively. The list of drugs considered has been provided in Appendix
15

I. 589 beneficiaries were thus identified to be in the exposed group. Similarly, Medicaid
beneficiaries identified as asthmatics and on ICS therapy were selected as the unexposed
population with the only difference being that these patients were not on concurrent statin
therapy. The inclusion criteria for the exposed as well as unexposed groups have been laid out in
Table I.
Table I: Inclusion criteria for the ‘exposed’ and ‘unexposed’ groups

‘EXPOSED’ ‘UNEXPOSED’
1. Diagnosed with Asthma
2. 180 day prescription history of statins prior to the
index date with a MPR ≥ 0.8
3. At least 1 prescription for an ICS 6 months prior to
index date
4. Continuous eligibility for a period of 18 months
beginning 6 months prior to and ending a year
after the index date

The study design included a washout period from January 1st 2002 to June 31st 2002 in
order to track the prescription records of patients identified and included in the study after June
31st 2002. The 589 subjects in the exposed group were matched to the 7390 subjects in the
unexposed group using propensity scores (within a range of ±0.005) computed using certain
covariates, which shall be explained in detail later. Each exposed subject was matched to 10
corresponding subjects from the unexposed group; following which the unexposed subjects were
assigned the index date of the exposed subjects they were matched to. This was done in order to
maximize the number of exposed subjects that had at least 2 corresponding subjects from the
16

unexposed group with an ICS prescription six months prior to the index date and were eligible
throughout the same period. 479 exposed subjects were thus obtained, along with corresponding
958 unexposed subjects and a detailed flow diagram representing this has been provided (Figure
III). The two cohorts were then followed for a period of one year beginning the index date, and
their outcomes in terms of hospitalizations and ER visits were compared.

Apr 2003

Mar 2004

Oct 2002

Jan 2002

Statins (‘Exposed’)

Identification of subjects

Sep 2003

Jan 2004

Jul 2002
Apr 2003

Mar 2004

Oct 2002

Sep 2003

Figure II. Graphical representation of the study design
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Dec 2004

No statins (‘Unexposed’)

Washout period

83,446 beneficiaries with a diagnosis of asthma

35,001 beneficiaries with at least 1 ICS prescription

2,742 beneficiaries with at least 1 statin prescription

589 ‘exposed’ beneficiaries with ≥80% adherence to
statin medication and at least 1 ICS prescription over
a period of 180 days between 1st January 2002 and
31st December 2003

479 ‘exposed’ beneficiaries each matched to two
‘unexposed’ beneficiaries meeting all the inclusion
criteria enlisted in Table I.

Figure III. Algorithm displaying how the final study subjects were identified.

Rationale for including only Asthmatics on Inhaled Corticosteroid Therapy
Inhaled Corticosteroids (ICSs) are the most consistently effective long-term control
medication at all steps of care for persistent asthma and they improve asthma control more
effectively than any other single long-term control medication.2 They are anti-inflammatory
medications that reduce airway hyper responsiveness, inhibit inflammatory cell migration and
activation and block late phase reaction to allergens.2 Statins are also hypothesized to be of
potential benefit in asthma management due to their anti-inflammatory properties and hence only
18

those patients on ICS therapy were included in the study design so as to avoid confounding. If
being on ICS therapy is not one of the inclusion criteria, the potential beneficial effect of statins
amongst the exposed population might be mitigated due to patients not on ICS therapy, in case
there are more subjects in the unexposed group on ICS therapy. Similarly, the results will be
affected if a larger number of exposed patients are on ICS therapy as compared to the unexposed.
ICSs are used for the control of asthma rather than for quick relief of symptoms and thus
majority of the asthmatic patients are expected to be on ICS therapy. Thus, it was feasible to
incorporate it into the study design as an inclusion criterion rather than control for it.

Study Variables
Covariates:
The exposed and unexposed groups were matched on the following variables using propensity
scoring.
i.

Age. The age of the subjects as of 31st December 2002 was computed using their date of
birth.

ii.

Gender. The two categories were:
Male
Female

iii.

Race. The three categories considered were:
Whites
Blacks
Others

iv.

Regions of Mississippi. The subjects were categorized into Rural and Urban based on the
county numbers listed in Appendix II. This variable was used to serve as an indication of the
access to care and control for differences in provider type.
19

v.

Comorbidities. The Charlson Comorbidity Index (CCI) was computed and used in the
calculation of the propensity scores.
The following variables were additionally controlled for in the analysis performed on the
matched cohorts.

i.

Adherence to ICS. The MPR was used as an indication of adherence to ICS therapy and was
computed for the six months prior to the index date for each subject53.

ii.

Average number of short-acting β agonists per subject. Short-acting β agonists are the most
effective therapy for rapid reversal of airflow obstruction and prompt relief of asthmatic
symptoms. The average number of short-acting β agonists per subject was computed for the
six months prior to the index date and was used as an indicator of the severity of the disease.
The list of drugs considered has been provided in Appendix I.

iii.

Prior hospitalizations due to asthma. The number of hospitalizations attributed to a primary
diagnosis of asthma in the six month washout period prior to the index date was used as an
indicator of the severity of the disease.

iv.

Prior ER visits due to asthma. In addition to the inpatient visits, the number of ER visits
attributed to a primary diagnosis of asthma in the six month washout period prior to the index
date was also used as an indicator of the severity of the disease.

v.

Prior office and lab visits due to asthma. The number of office and lab visits attributed to a
primary diagnosis of asthma six months prior to the index date was accounted for as an
additional measure of severity of the disease.
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Outcome variables
i.

Hospitalization due to asthma. Hospitalization due to asthma was one of the outcome
variables based on which the exposed subjects were compared against the unexposed group.
The variable was coded dichotomously (as occurrence and non-occurrence of event), using
the principal diagnosis code for hospitalization, through one year post the index date for both
the exposed and unexposed groups.

ii.

ER visits due to asthma. ER visit was used as a measure of the outcomes similar to the
hospitalization visits. Again the occurrence or non-occurrence of an ER visit one year post
the index date for each subject was computed.

iii.

Costs due to asthma. The prescription, inpatient visit, ER visit, office and lab visit costs due
to asthma, from Medicaid’s perspective, was used to calculate the costs incurred. The
prescription costs due to statins will be taken into account for the exposed group.

Analysis Plan
The following two hypotheses were tested using the described analyses.
Hypothesis 1: Asthmatic patients on concurrent statin therapy are less likely to have asthmarelated hospitalizations and ER visits.
Hypothesis 2: Asthmatic patients on concurrent statin therapy bear lesser costs due to the
management of asthma.
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Descriptive statistics were reported for the exposed and unexposed subjects pre- and postmatching. PROC MEANS with the t-test option specified was used to compute mean and
standard deviations along with differences in the average age and CCI of the two cohorts preand post-matching. Similarly, PROC FREQ was used to compute frequencies and percentages
for categorical variables such as gender, race and region and to determine differences in
percentages across these variables between the two cohorts pre- and post matching.
After the identification of the exposed and unexposed based on the inclusion criteria
described previously, propensity scores (PS) were calculated for the subjects in both groups. The
propensity score for an individual is defined as the conditional probability of being treated given
the individual’s covariates and thus reduces bias by balancing the covariates in the two groups.
PROC LOGISTIC was used to compute and save the probability of being in the exposed group
for all subjects based on their age, gender, race, region and CCI as discussed previously.
After the matched exposed and unexposed cohorts were obtained, the two groups were
analyzed using conditional logistic regression, via PROC LOGISTIC with the STRATA option
specified, to compare the hospitalization and ER visits and test hypothesis 1. The difference in
the costs accrued by the two groups was analyzed using a general linear model accounting for the
dependencies in the data.
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IV. RESULTS
As discussed previously, 589 subjects met the inclusion criteria for the exposed cohort
and the pool of unexposed subjects comprised of 7,390 individuals prior to matching on the
propensity scores. The average age of asthma patients on concurrent statin therapy was
significantly higher than that of patients not on statin therapy (48.87 [±0.22] vs. 63.28 [±0.5]; p <
0.0001). A significantly higher proportion of asthma patients who were not on concurrent statin
therapy were black as compared to those on statin therapy (54.44% vs. 42.95%; p < 0.0001)
before matching (Table II). Additionally, those on concurrent statin therapy had a significantly
higher average CCI than those not on concurrent statin therapy (4.01[±0.10] vs. 2.65 [± 0.03]; p
< 0.0001).
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Table II. Sample descriptives before matching
Characteristic
Age, mean (SD)

Exposed
(589)
63.28 (± 0.50)

Unexposed
(7390)
48.87 (± 0.22)

Gender, n (%)
Male
Female

125 (21.22%)
464 (78.78%)

1642 (22.22%)
5748 (77.78%)

Race, n (%)
White
Black
Other

334 (56.71%)
253 (42.95%)
2 (0.34%)

3321 (44.94%)
4023 (54.44%)
46 (0.62%)

Region, n (%)
Urban
Rural
Charleson Comorbidity Index,
mean (SD)

P
<.0001*
0.5750

<.0001*

0.0544
167 (28.35%)
422 (71.65%)

2379 (32.19%)
5011 (67.81%)

4.01 (± 0.10)

2.65 (± 0.03)

<.0001*

* p < 0.05

The spread of the computed propensity of being in the exposed cohort for each subject in
the study before matching is displayed in Figure IV.
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Figure IV. Distribution of propensity scores before matching

After matching, the exposed cohort comprised of 479 individuals with 958 individuals in
the unexposed cohort. Post-matching on propensity scores, a significantly higher proportion of
asthma patients on concurrent statin therapy were from the rural areas of Mississippi (71.19% vs.
65.45%; p = 0.0287) as compared to those not on statin therapy (Table III). Additionally, the
average CCI of patients on concurrent statin therapy was higher than that of patients not on statin
therapy (3.75 [±0.10] vs. 3.48 [±0.07]; p = 0.03).
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Table II. Sample descriptives after matching
Characteristic
Age, mean (SD)
Gender, n (%)
Male
Female
Race, n (%)
White
Black
Other
Region, n (%)
Urban
Rural
Charleson Comorbidity
Index, mean (SD)

Exposed
(479)

Unexposed
(958)

P

62.59 (0.55)

63.48 (0.42)

0.2124
0.1994

101 (21.09%)
378 (78.91%)

231 (24.11%)
727 (75.89%)
0.4716

269 (56.16%)
208 (43.42%)
2 (0.42%)

540 (56.37%)
417 (43.53%)
1 (0.1%)
0.0287*

138 (28.81%)
341 (71.19%)

331 (34.55%)
627 (65.45%)

3.75 (±0.10)

3.48 (±0.07)

0.0300*

* p < 0.05

The range of the propensity scores of each individual in the study post-matching has been
shown in Figure V.
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Figure V. Distribution of propensity scores after matching

The proportion of exposed and unexposed subjects using additional medications, besides
ICS, for asthma management has been reported in Table IV.
Table IV. Additional medications used for asthma management
Unexposed
Medication
(958)
n (%)
Mast cell stabilizers
2 (<1)
5 (<1)
Leukotriene modifiers
134 (28)
318 (33)
Long- acting β agonists
48 (10)
126 (13)
Theophylline
42 (9)
142 (15)
Ipratropium
31 (6)
100 (10)
Short-acting β agonists (SABA)
180 (38)
462 (48)
Oral corticosteroids
81 (17)
294 (31)
* The list of drugs considered for each of the above classes has been provided in Appendix I
Exposed (479)
n (%)
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Descriptive information on the various covariates adjusted for in the final conditional
logistic regression model has been provided in Table V.
Table V. Descriptives of covariates adjusted for

Characteristic
Adherence to ICS therapy (Proportion of days covered)
Average no. of SABA prescriptions per subject
No. of asthma office & lab visits 6 months prior the
index date
No. of asthma hospitalization events 6 months prior the
index date
No. of asthma ER events 6 months prior the index date

Exposed
(479)
mean, (SD)
0.47
(0.2684)

Unexposed
(958)
mean, (SD)
0.51
(0.2811)

2.74 (2.10)

3.49 (2.85)

0.21
(0.6375)
0.03
(0.1860)
0.02
(0.1359)

0.24
(0.6535)
0.05
(0.2406)
0.06
(0.2908)

P value
0.0146*
<.0001*
0.5031
0.1002
0.0063*

* p < 0.05
The proportion of the exposed and unexposed subjects where the occurrence of the
outcome events were observed, have been reported in Table VI.
Table VI. Occurrence of the outcomes studied

Outcome
≥1 asthma hospitalization events 12 months post index date
≥1 asthma ER events 12 months post index date

Exposed
(479)
n (%)
19 (3.79)
20 (4.18)

Unexposed
(958)
n (%)
62 (6.47)
87 (9.08)

Table VII represents the results of the conditional logistic regression conducted on the
matched data to obtain the odds of hospitalization/ER admission due to asthma amongst patients
on concurrent statin therapy as opposed to those not on statin therapy. Asthma patients not on
concurrent statin therapy were almost two times as likely to have hospital visits and/or ER visits
or both due to asthma (unadjusted OR = 0.51; 95% CI [0.34, 0.76]), in comparison to patients on
28

statin therapy. Similarly, they were also more likely to be hospitalized (unadjusted OR = 0.56;
95% CI [0.32, 0.98]) and visit the ER (unadjusted OR = 0.44; 95% CI [0.27, 0.73]) due to
asthma exacerbations as opposed to those on statin therapy. The above odds ratios have not been
adjusted for additional variables such as prior asthma-related hospitalizations, ER visits, office
and lab visits and adherence to ICS therapy. The adjusted conditional odds ratios after
accounting for all the above mentioned factors have also been reported in Table VII. Asthma
patients not on concurrent statin therapy were almost two times as likely to have hospitalization
and/or ER visits or both due to asthma (adjusted OR = 0.55; 95% CI [0.36, 0.84]; p = 0.0059), in
comparison to patients on statin therapy. Similarly, they were also significantly more likely to
visit the ER due to asthma exacerbations when compared to patients on statins (adjusted OR =
0.47; 95% CI [0.28, 0.82]; p = 0.0069).
Table VII. Conditional odds ratios of hospitalizations due to asthma associated with statin use.

Outcome
Asthma hospitalization
and/or ER visit
Asthma hospitalization
Asthma ER visit

Unadjusted OR
(95% CI)
0.511
(0.342 – 0.762)
0.562
(0.321 – 0.983)
0.442
(0.269 – 0.726)

P value
0.0010*
0.0436*
0.0013*

Adjusted OR
(95% CI)
0.547
(0.356 – 0.840)
0.629
(0.352 – 1.125)
0.474
(0.275 – 0.815)

P value
0.0059*
0.1183
0.0069*

* p < 0.05
When the costs incurred per subject due to asthma were compared across the two groups,
the average prescription costs due to asthma ($1,166 [± $1,005] vs. $1,536 [± $1,303]; p =
<.0001), hospitalization ($125 [±$710] vs. $252[±1,264]; p = 0.0376) and ER visit ($3 [± $19]
vs. $10 [± $47]; p <.0013) costs incurred by patients not on concurrent statin therapy over the
study period (18 months) are significantly higher (Table VIII). Similarly, the average total costs
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inclusive of prescription, hospitalization, ER, office and lab visit costs due to asthma were
significantly higher for patients not on concurrent statin therapy when compared to those on
statin therapy ($1,852 [± $1,944] vs. $1,337[$1,264]; p <.0001). However, when the
prescription costs due to statins are included for the exposed patients, the average total costs
were significantly higher for patients on concurrent statin therapy when compared to those not on
statin therapy ($2,578 [$1,373] vs. $1,852 [$1,944]; p < .0001).
Table VIII. Average costs incurred per patient over the study period (18 months)
Costs
Due to asthma
Prescription
Hospitalization
ER
Office & lab
Total
Statin therapy costs
Total
* p < 0.05

Exposed (479),
mean (SE)

Unexposed (958),
mean (SE)

P

$1,166 ($1,005)
$125 ($710)
$3 ($19)
$42 ($116)
$1,337 ($1,264)

$1,536 ($1,303)
$252 ($1,264)
$10 ($47)
$53 ($128)
$1,852 ($1,944)

<.0001*
0.0376*
0.0013*
0.0961
<.0001*

$1,241 ($501)
$2,578 ($1,373)

NA
$1,852 ($1,944)

NA
<.0001*
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V. DISCUSSION
This study aims at exploring the benefits of statins on asthma outcomes such as ER visits
and hospitalizations, using the Mississippi Medicaid claims data (2002-2004). Using a
retrospective cohort study design we compared the outcomes of asthma patients on concurrent
statin therapy versus those not on statin therapy. Further the costs incurred by Medicaid due to
asthma were also compared across the two groups.
Over the three years of data analyzed, 589 subjects met the inclusion criteria for the
exposed cohort, prior to matching and were classified as subjects on statin therapy, with 7,390
subjects in the unexposed cohort. When comparing the demographic characteristics of patients
on concurrent statin therapy to those not on statins, significant differences were observed. The
average age of the asthmatic patients on statin therapy was significantly higher than those not on
statin therapy. This is not surprising as patients with statin therapy would likely have a codiagnosis of hyperlipidemia, a condition more prevalent in older adults. Additionally, a
significantly higher proportion of patients on statin therapy were white when compared to the
unexposed population and also had a higher average CCI score. In order to control for the above
differences, propensity scores were computed and the study groups were matched on their
propensity to be in the exposed cohort. The two groups could have been directly matched on
each of the covariates listed in Table II; however, this would lead to a considerable decrease in
the sample size and hence was not preferred. Additionally, the outcome events, i.e.
hospitalizations and ER visits due to asthma 12 months post the index date, were observed in
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5.67% and 7.4% of the study subjects, respectively. This can be considered a rare outcome and
therefore, using propensity scores was considered suitable. After matching, there were 479
subjects in the exposed group and 958 corresponding controls.
The final sample comprised of considerably older subjects with the average age of the
exposed and unexposed being 62.59 (±0.55) years and 63.48 (±0.42) years, respectively. A
majority of them were females, which is consistent with previous prevalence reports which
indicate that asthma is more prevalent in females21 in general. Additionally, a higher proportion
of the sample was white, belonged to rural regions and had a considerable number of comorbid
conditions as is evident from the higher average CCI score.
A higher proportion of the unexposed subjects were on additional asthma controller
therapy, besides ICS, such as mast cell stabilizers, leukotriene modifiers, long-acting β agonists,
theophylline, ipratropium, short-acting β agonists and oral corticosteroids. Short-acting β
agonists are the most effective therapy for rapid reversal of airflow obstruction and prompt relief
of asthmatic symptoms.25 Thus, the average number of short-acting β agonist prescriptions per
patient was controlled for in the final analysis as an indicator of the severity of the condition. It
is interesting to note however, that the average number of short-acting β agonist prescriptions
were significantly higher for patients not on statin therapy and thus one might expect their
condition to be better managed, which does not seem to be the case. Thus, the other way to look
at it is that their condition is more severe or is not being managed well and hence the higher
average number of quick relief prescriptions.
The additional factors controlled for included adherence to ICS therapy, average number
of short-acting β agonist prescriptions per subject, prior hospitalizations, ER, lab and office visits
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due to asthma. The adherence to ICS therapy among the study subjects was considerably low,
with the exposed and unexposed subjects being 47% and 51% adherent, respectively. It is
important to note here that the unexposed cohort in this study did have higher adherence rates to
ICS therapy. Systematic reviews conducted by the Cochrane collaboration of the adherence to
ICS therapy literature, also suggest underuse of prescribed ICSs on 24% to 69% of days.54
Additional studies assessing prescription refills of ICSs report MPRs within a range of 8% to
50%.53,55-58 Thus the low adherence among our study subjects is not surprising, and was
controlled for as it is associated with adverse asthma outcomes. However, this also brings to
light that adherence to ICS therapy is a problem and more effort is required to help patients
better manage their asthma.
The average number of asthma hospitalizations, ER, office and lab visits per subject over
a period of 6 months is consistent with the rates reported by the National Surveillance for
Asthma 2001-2003.21 The report mentions an average annual 61.2 office visits, 8.8 ER visits and
2.5 hospitalizations for asthma per 100 persons with current asthma.
A significant reduction in the odds of hospitalization and ER visits due to asthma was
found to be associated with statin use. Even after controlling for the cofounders mentioned
above, patients not on concurrent statin therapy were almost twice as likely to have
hospitalization and/or ER visits attributable to asthma when compared to patients on statin
therapy. These findings are in accordance with the only other observational study13 conducted to
investigate the beneficial effects of statins in asthma therapy. The authors reported that statin
therapy was associated with a 33% lower risk of hospitalization or ER visit for asthma in adult
asthmatic patients on inhaled corticosteroid therapy. The difference in the results reported in our
study could be attributable to the differences in the dataset as well as methodology used. We
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conducted our analyses on matched cohorts and additional factors such as adherence to ICS
medication, prior hospitalizations, ER, lab and office visits due to asthma were accounted for, in
order to control for the severity of the condition. Additionally, the proportions of subjects in
both groups on additional controller medications for asthma have also been reported. Although,
the study conducted by Stanek and colleagues is the only other that analyzes claims data, further
support for the beneficial role of statins in asthma is found in numerous animal model studies.4-10
There are several limitations of this study. The study was conducted using Medicaid
claims data and therefore there is a possibility of misclassification due to coding errors during
claims processing. Further, even though the subjects in the unexposed group were matched to
the exposed population based on their propensity scores, significant differences between the two
groups were still observed when compared across their CCI scores and the region (urban versus
rural) to which they belonged. This could be attributed to two plausible explanations. Firstly, the
cohorts were matched on propensity scores allowing a range of ±0.005. Secondly, each subject
was initially matched to 10 corresponding subjects from the unexposed pool, following which
two controls were selected based on their continuous eligibility throughout the study period and
ICS prescription records within 180 days prior to the index date. However, both of the above
measures were incorporated into the study design to maximize the sample size. The subjects on
statin therapy had a significantly higher average CCI score compared to those not on statin
therapy. It is unlikely that this difference could have biased the findings towards a lower risk of
hospitalization due to asthma in these subjects. Further, the average age of the population
studied was around 63 years, which suggests that a considerable number of subjects were dualeligibles. Thus some might suggest that all the claims for this population might not be present in
the dataset as Medicare is their primary payer. However, since Medicaid contributes towards the
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copayment one can argue that the claim would still be present in the dataset; however, the total
costs associated with that claim will not be available. Thus, although this should not bias the
results of the conditional logistic regression, a potential limitation would be that the costs
associated with asthma hospitalization are likely to be underestimated. Additionally, the
population studied had an average age of approximately 63 years and were sicker patients in
general due to the higher CCI scores, which limits the generalizability of the study to some
extent.
The total average per person cost of asthma over the study period (18 months) is $1,337
(±$1,264) for those on concurrent statin therapy and $1,852 (±$1,944) for those not on statins.
However, when statin prescription costs are included, the average total costs for the exposed
group amounts to $2,578 (±1,373). Thus, the results are not in favor of our proposed hypotheses.
However, these need to be interpreted with caution as they may be underestimated, as mentioned
above, due to dual-eligibility. The average direct annual cost of asthma per-person reported
using cross-sectional survey data of 401 adults with asthma is $3,180,59 which is higher than the
costs reported in our study. Further the average ER and hospitalization costs reported in our
study are very low. An explanation for this observation may be the fact that these events were
observed in few patients thus decreasing the average considerably.
The findings of this study contribute significantly to the growing body of literature that
suggests statins have beneficial effects in preventing asthma exacerbations. However, further
investigation employing different datasets, different methodologies and accounting for other
confounding variables which may have been overlooked, is required to provide conclusive
evidence. Although, two clinical trials11,12 conducted earlier have failed to show clinically
important improvements in asthma symptoms and a range of other clinical indices in asthma
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control, these suffer from sample size limitations and hence their results should be interpreted
with caution. Further, the results of a recent animal model study 10, although supporting the antiinflammatory effects of simvastatin suggest that the effect of simvastatin on lung inflammation
in asthma are controversial and differ between species. Thus, in the light of the evidence so far,
and considering the results of this study, the role of statins in the treatment of asthma definitely
warrants further investigation.
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APPENDIX I
List of statins and statin combinations considered
•
•
•
•
•
•

•
•
•
•
•
•

Amlodipine-atorvastatin
Aspirin-pravastatin
Atorvastatin
Cerivastatin
Ezetimibe-simvastatin
Fluvastatin

Lovastatin
Lovastatin-niacin
Niacin-simvastatin
Pravastatin
Rosuvastatin
Simvastatin

List of inhaled corticosteroids and combination drugs with inhaled corticosteroids considered
•
•
•
•
•

•
•
•
•

Beclomethasone
Budenoside
Budesonide-formoterol
Ciclesonide
Flunisolide

Fluticasone
Fluticasone-salmeterol
Mometasone
Triamcinolone

List of drugs considered as additional controller therapy for asthma management
 Mast cell stabilizers
• Cromolyn
• Nedocromil

 Methylxanthines
• Theophylline
 Short-acting β agonists
• Albuterol
• Levalbuterol
• Pirbuterol

 Leukotriene modifiers
• Montelukast
• Zafirlukast
• Zileuton

 Systemic corticosteroids
• Methylprednisolone
• Prednisolone
• Prednisone

 Long-acting β agonists
• Formoterol
• Salmeterol
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APPENDIX II
Rural/Urban county codes for counties in Mississippi
2003 Ruralurban
Continuum
Code

2000
Population

Alcorn County

7

34,558

MS

Amite County

8

13,599

28007

MS

Attala County

6

19,661

28009

MS

Benton County

8

8,026

28011

MS

Bolivar County

5

40,633

28013

MS

Calhoun County

7

15,069

28015

MS

Carroll County

9

10,769

28017

MS

Chickasaw
County

7

19,440

28019

MS

Choctaw County

9

9,758

28021

MS

Claiborne County

6

11,831

28023

MS

Clarke County

9

17,955

28025

MS

Clay County

7

21,979

28027

MS

Coahoma County

5

30,622

28029

MS

2

28,757

28031

MS

8

19,407

28033

MS

Copiah County
Covington
County
DeSoto County

1

107,199

Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
Nonmetro county completely rural or less than 2,500 urban population, adj. to
metro area
Nonmetro county with urban population of 2,500-19,999, adjacent to a metro
area
Nonmetro county completely rural or less than 2,500 urban population, adj. to
metro area
Nonmetro county with urban population of 20,000 or more, not adjacent to a
metro area
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
Nonmetro county completely rural or less than 2,500 urban population, not adj.
to metro area
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
Nonmetro county completely rural or less than 2,500 urban population, not adj.
to metro area
Nonmetro county with urban population of 2,500-19,999, adjacent to a metro
area
Nonmetro county completely rural or less than 2,500 urban population, not adj.
to metro area
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
Nonmetro county with urban population of 20,000 or more, not adjacent to a
metro area
County in metro area of 250,000 to 1 million population
Nonmetro county completely rural or less than 2,500 urban population, adj. to
metro area
County in metro area with 1 million population or more

28035

MS

Forrest County

3

72,604

County in metro area of fewer than 250,000 population

FIPS
Code

State

28003

MS

28005

County Name

Description for 2003 codes
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Rural/Urban code
used in study
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
1
1

28037

MS

Franklin County

9

8,448

28039

MS

George County

3

19,144

28041

MS

Greene County

8

13,299

28043

MS

Grenada County

7

23,263

28045

MS

Hancock County

3

42,967

Nonmetro county completely rural or less than 2,500 urban population, not adj.
to metro area
County in metro area of fewer than 250,000 population
Nonmetro county completely rural or less than 2,500 urban population, adj. to
metro area
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
County in metro area of fewer than 250,000 population

28047

MS

Harrison County

3

189,601

County in metro area of fewer than 250,000 population

1

28049

MS

Hinds County

2

250,800

1

28051

MS

Holmes County

6

21,609

28053

MS

Humphreys
County

7

11,206

28055

MS

Issaquena County

9

2,274

28057

MS

Itawamba County

7

22,770

28059

MS

Jackson County

3

131,420

28061

MS

Jasper County

9

18,149

28063

MS

Jefferson County

7

9,740

28065

MS

Jefferson Davis
County

8

13,962

28067

MS

Jones County

4

64,958

28069

MS

Kemper County

9

10,453

28071

MS

Lafayette County

6

38,744

28073

MS

3

39,070

28075

MS

Lamar County
Lauderdale
County

5

78,161

28077

MS

Lawrence County

8

13,258

28079

MS

Leake County

6

20,940

28081

MS

Lee County

5

75,755

County in metro area of 250,000 to 1 million population
Nonmetro county with urban population of 2,500-19,999, adjacent to a metro
area
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
Nonmetro county completely rural or less than 2,500 urban population, not adj.
to metro area
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
County in metro area of fewer than 250,000 population
Nonmetro county completely rural or less than 2,500 urban population, not adj.
to metro area
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
Nonmetro county completely rural or less than 2,500 urban population, adj. to
metro area
Nonmetro county with urban population of 20,000 or more, adjacent to a metro
area
Nonmetro county completely rural or less than 2,500 urban population, not adj.
to metro area
Nonmetro county with urban population of 2,500-19,999, adjacent to a metro
area
County in metro area of fewer than 250,000 population
Nonmetro county with urban population of 20,000 or more, not adjacent to a
metro area
Nonmetro county completely rural or less than 2,500 urban population, adj. to
metro area
Nonmetro county with urban population of 2,500-19,999, adjacent to a metro
area
Nonmetro county with urban population of 20,000 or more, not adjacent to a
metro area
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0
1
0
0
1

0
0
0
0
1
0
0
0
0
0
0
1
0
0
0
0

28083

MS

Leflore County

5

37,947

28085

MS

Lincoln County

6

33,166

28087

MS

Lowndes County

5

61,586

28089

MS

Madison County

2

74,674

28091

MS

Marion County

6

25,595

28093

MS

Marshall County

1

34,993

28095

MS

Monroe County

7

38,014

28097

MS

Montgomery
County

7

12,189

28099

MS

Neshoba County

7

28,684

28101

MS

Newton County

7

21,838

28103

MS

Noxubee County

7

12,548

28105

MS

Oktibbeha
County

5

42,902

28107

MS

Panola County

6

34,274

28109

MS

6

48,621

28111

MS

Pearl River
County
Perry County

3

12,138

28113

MS

Pike County

7

38,940

28115

MS

Pontotoc County

7

26,726

28117

MS

Prentiss County

7

25,556

28119

MS

Quitman County

6

10,117

28121

MS

Rankin County

2

115,327

28123

MS

Scott County

6

28,423

28125

MS

Sharkey County

9

6,580

28127

MS

Simpson County

2

27,639

Nonmetro county with urban population of 20,000 or more, not adjacent to a
metro area
Nonmetro county with urban population of 2,500-19,999, adjacent to a metro
area
Nonmetro county with urban population of 20,000 or more, not adjacent to a
metro area
County in metro area of 250,000 to 1 million population
Nonmetro county with urban population of 2,500-19,999, adjacent to a metro
area
County in metro area with 1 million population or more
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
Nonmetro county with urban population of 20,000 or more, not adjacent to a
metro area
Nonmetro county with urban population of 2,500-19,999, adjacent to a metro
area
Nonmetro county with urban population of 2,500-19,999, adjacent to a metro
area
County in metro area of fewer than 250,000 population
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
Nonmetro county with urban population of 2,500-19,999, adjacent to a metro
area
County in metro area of 250,000 to 1 million population
Nonmetro county with urban population of 2,500-19,999, adjacent to a metro
area
Nonmetro county completely rural or less than 2,500 urban population, not adj.
to metro area
County in metro area of 250,000 to 1 million population
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0
0
0
1
0
1
0
0
0
0
0
0
0
0
1
0
0
0
0
1
0
0
1

28129

MS

Smith County

8

16,182

28131

MS

3

13,622

28133

MS

5

34,369

28135

MS

7

14,903

28137

MS

Stone County
Sunflower
County
Tallahatchie
County
Tate County

1

25,370

28139

MS

Tippah County

7

20,826

28141

MS

8

19,163

28143

MS

Tishomingo
County
Tunica County

1

9,227

28145

MS

Union County

7

25,362

28147

MS

Walthall County

9

15,156

28149

MS

Warren County

4

49,644

28151

MS

Washington
County

5

62,977

28153

MS

Wayne County

7

21,216

28155

MS

Webster County

9

10,294

28157

MS

Wilkinson
County

8

10,312

28159

MS

Winston County

7

20,160

28161

MS

Yalobusha
County

7

13,051

28163

MS

Yazoo County

6

28,149

Nonmetro county completely rural or less than 2,500 urban population, adj. to
metro area
County in metro area of fewer than 250,000 population
Nonmetro county with urban population of 20,000 or more, not adjacent to a
metro area
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
County in metro area with 1 million population or more
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
Nonmetro county completely rural or less than 2,500 urban population, adj. to
metro area
County in metro area with 1 million population or more
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
Nonmetro county completely rural or less than 2,500 urban population, not adj.
to metro area
Nonmetro county with urban population of 20,000 or more, adjacent to a metro
area
Nonmetro county with urban population of 20,000 or more, not adjacent to a
metro area
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
Nonmetro county completely rural or less than 2,500 urban population, not adj.
to metro area
Nonmetro county completely rural or less than 2,500 urban population, adj. to
metro area
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
Nonmetro county with urban population of 2,500-19,999, not adjacent to a
metro area
Nonmetro county with urban population of 2,500-19,999, adjacent to a metro
area

*Information available at http://www.ers.usda.gov/Data/RuralUrbanContinuumCodes/
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0
1
0
0
1
0
0
1
0
0
0
0
0
0
0
0
0
0
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